Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TENX 
Tenax Therapeutics Inc (TENX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TENX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.5
1 Year Target Price $18.5
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.56% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.68M USD | Price to earnings Ratio 3.52 | 1Y Target Price 18.5 |
Price to earnings Ratio 3.52 | 1Y Target Price 18.5 | ||
Volume (30-day avg) 4 | Beta 1.46 | 52 Weeks Range 3.25 - 7.89 | Updated Date 08/15/2025 |
52 Weeks Range 3.25 - 7.89 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -39.78% |
Valuation
Trailing PE 3.52 | Forward PE 0.3 | Enterprise Value 15578332 | Price to Sales(TTM) - |
Enterprise Value 15578332 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 4148500 | Shares Floating 4091921 |
Shares Outstanding 4148500 | Shares Floating 4091921 | ||
Percent Insiders 0.23 | Percent Institutions 71.52 |
Upturn AI SWOT
Tenax Therapeutics Inc
Company Overview
History and Background
Tenax Therapeutics, Inc. (TENX) is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for critical care markets. Founded in 2004 and re-branded in 2011, the company has concentrated on acute cardiovascular conditions and pulmonary hypertension.
Core Business Areas
- Critical Care: Focuses on developing and commercializing therapies for unmet needs in acute cardiovascular and pulmonary conditions. Primary focus is imatinib for pulmonary hypertension.
Leadership and Structure
The leadership team consists of seasoned pharmaceutical executives and scientists. The organizational structure is typical of a small biotech company, with functional departments such as research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Imatinib: Tenax Therapeutics is focused on the development of oral imatinib for the treatment of Pulmonary Arterial Hypertension (PAH) . There is currently no market share or revenue data available because imatinib is not yet approved for PAH. Competitors in the PAH market include United Therapeutics (UTHR), Johnson & Johnson (JNJ), and Bayer (BAYRY).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in critical care, is characterized by high regulatory hurdles, long development timelines, and significant investment requirements. Demand for innovative treatments for cardiovascular and pulmonary conditions remains high.
Positioning
Tenax Therapeutics aims to fill unmet needs in the acute cardiovascular and pulmonary hypertension space with imatinib. It operates as a smaller company compared to large pharmaceutical players.
Total Addressable Market (TAM)
The PAH market is estimated to be worth billions of dollars annually. Tenax Therapeutics, if successful with imatinib, could capture a portion of this market. The exact size is dependent on approval and uptake rates.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical needs
- Experienced leadership team
- Potential for orphan drug designation
- Proprietary drug candidate (Imatinib) targeting PAH
Weaknesses
- Limited financial resources
- Dependence on a single drug candidate
- High regulatory risk
- History of operating losses and dependence on external funding
Opportunities
- Successful clinical trial outcomes
- FDA approval and market launch of Imatinib
- Strategic partnerships or collaborations
- Expansion into other critical care areas
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from established pharmaceutical companies
- Patent challenges
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- UTHR
- JNJ
- BAYRY
- MRK
- BMY
Competitive Landscape
Tenax Therapeutics faces stiff competition from larger, well-established pharmaceutical companies in the cardiovascular and pulmonary disease market. Its success hinges on differentiation through imatinib's efficacy and safety profile, if approved.
Growth Trajectory and Initiatives
Historical Growth: Tenax Therapeutics' growth has been limited due to its development stage.
Future Projections: Future growth is dependent on successful development and commercialization of imatinib, but can not be confirmed. Analyst estimates are limited at this time.
Recent Initiatives: Focusing on the development of Imatinib for PAH and managing their financial situation through measures like reverse stock splits.
Summary
Tenax Therapeutics is a clinical-stage biotech company focused on imatinib for PAH. Its success depends on positive clinical trial outcomes and regulatory approval. The company operates in a competitive market with limited financial resources, which presents significant risks. Overcoming these challenges will be crucial for future growth and success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings, Company website, Industry reports, Analyst reports.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be outdated. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenax Therapeutics Inc
Exchange NASDAQ | Headquaters Chapel Hill, NC, United States | ||
IPO Launch date 1997-01-02 | CEO, President & Director Mr. Christopher T. Giordano | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.tenaxthera.com |
Full time employees 4 | Website https://www.tenaxthera.com | ||
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.